Nomura Reports WUXI APPTEC (02359.HK) Exceeds Expectations in 4Q25; Anticipates Continued Growth This Year
Positive Profit Alert: WUXI APPTEC forecasts a 15.8% YoY revenue growth for 2025, reaching RMB45.5 billion, exceeding previous guidance and market expectations for 4Q25.
Strong Performance Drivers: The company's growth is attributed to its chemical business and clinical CRO revenue, with a projected net profit increase of 103% to RMB19.2 billion, aided by the sale of WUXI XDC.
Analyst Ratings: Nomura maintains a Buy rating for WUXI APPTEC, with an unchanged target price of HKD132.8, citing positive operational data for 4Q25 and sustained growth momentum into 2026.
Market Context: CLSA has set a target price of HKD143.4 for WUXI APPTEC, indicating that the company's quarterly results have outperformed expectations and are likely to continue exceeding market performance this year.
Trade with 70% Backtested Accuracy
Analyst Views on 02268
About the author
S Korean Investors' Top HK Stock Purchase This Year: MINIMAX, Totaling USD 20.7M
Top Stock Purchases: As of February 10, 2026, South Korean investors' most purchased stock on the Hong Kong Stock Exchange is MINIMAX-WP (00100.HK) with a net purchase of approximately USD20.7 million, followed by CAM CSI300 (03188.HK) and MONTAGE TECH (06809.HK).
Shift in Investment Focus: Compared to 2025, South Korean investors are increasingly targeting China's emerging industries and tech companies, indicating a strategic shift in their investment approach.
Nomura Raises WUXI BIO (02269.HK) Price Target to $50.54 Following Strong Preliminary 2025 Results
WUXI BIO Profit Forecast: WUXI BIO projects a 16.7% YoY revenue growth for 2025, reaching RMB21.8 billion, surpassing market expectations of RMB21.5 billion.
Gross Margin and Net Profit Expectations: The company anticipates a gross margin increase to 46% and a net profit rise of 45.3% YoY to RMB5.7 billion, both exceeding market estimates.
Impact of WUXI XDC: Nomura highlights WUXI XDC as a key driver for revenue growth, with 2H25 revenue expected to grow by 12% YoY, up from 9% in 1H25.
Target Price Adjustment: Nomura raised WUXI BIO's target price from $37.36 to $50.54, maintaining a "Buy" rating based on the positive outlook.
Nomura Raises WUXI XDC (02268.HK) Price Target to $87.73, Anticipates 47% Profit Increase This Year
Nomura's Forecast Adjustment: Nomura has reduced its 2025 revenue and profit forecasts for WUXI XDC by 4.5% and 8.7%, respectively, based on recent company data.
Revenue Expectations: The broker projects revenue from commercial stage projects to reach RMB181 million and anticipates an additional RMB150 million from the acquisition of BIODLINK-B.
Profit Growth Projection: Nomura expects a 47% increase in profit for WUXI XDC in 2026, leading to an upward revision of the target price from $82.72 to $87.73.
Investment Rating: The rating for WUXI XDC has been maintained at "Buy" following the adjustments in forecasts and target price.
JPM Identifies Chinese Stocks Most Affected by RMB Appreciation's Negative Earnings Impact (Table)
Stock Performance Overview: Various stocks showed mixed performance with notable gains for SHENZHOU INTL (+2.953%) and SMIC (+2.061%), while others like UNIVERSAL SCIENTIFIC (-2.412%) and COWELL (-0.682%) experienced declines.
Short Selling Data: Significant short selling activity was observed, particularly in SMIC ($217.14M) and WUXI BIO ($160.63M), indicating market skepticism towards these stocks.
Estimated Impact of RMB Appreciation: The estimated impact of a 5% appreciation of the RMB against the USD on net profit varies, with some companies projected to face high single-digit impacts while others may see declines around 10-15%.
Market Outlook: UOB Kay Hian maintains a constructive medium-term view on markets, adding stocks like BABA and GANFENGLITHIUM to their buy list, while placing MEITUAN on the sell list.
G Sachs: This Year, China's Healthcare Sector Depends More on Data and Earnings Clarity; Favorable Outlook for CDMO Companies
Healthcare Sector Outlook: Goldman Sachs predicts that the strong trend in China's healthcare sector will continue, with stock trading increasingly focused on companies' execution capabilities and R&D pipelines rather than just licensing expectations.
CDMO Companies Favorable: The broker is optimistic about CDMO companies due to their growth potential and reasonable valuations, upgrading WUXI APPTEC and WUXI XDC to Buy.
Selective Biotech and Pharma Strategy: Goldman Sachs favors biotech and pharmaceutical companies with promising data releases and transaction expectations, highlighting SKB BIO-B, HENLIUS, and HANSOH PHARMA as favorable investments.
Cautious on Medical Services: The broker maintains a neutral stance on the medical devices sector and is cautious about medical services due to cost control measures and weak consumption, downgrading HYGEIA HEALTH and JXR to Neutral/Sell.
HSI Declines 11 Points at Midday; POP MART Soars Over 8%; Consumer Stocks Rise Against Market Trends
Market Performance: The HSI closed down 11 points at 26,552, with the HSCEI and HSTECH also experiencing slight declines. Total market turnover for the half-day was HKD129.845 billion.
Tech Stock Movements: Major tech stocks like TENCENT and BIDU-SW fell by approximately 1.5%, while JD-SW and BILIBILI-W saw gains of around 1.1% and 1.2%, respectively.
Sector Highlights: Consumer stocks performed well, with POP MART surging 8.5% after announcing a share buyback, while pharmaceutical stocks like HENGRUI PHARMA and WUXI APPTEC faced significant declines.
Economic Indicators: China's Fixed Asset Investment for December showed a year-on-year decrease of -3.8%, and the GDP growth rate for Q4 was reported at 4.5%, slightly below expectations.
S Korean Investors' Top HK Stock Purchase This Year: MINIMAX, Totaling USD 20.7M
Top Stock Purchases: As of February 10, 2026, South Korean investors' most purchased stock on the Hong Kong Stock Exchange is MINIMAX-WP (00100.HK) with a net purchase of approximately USD20.7 million, followed by CAM CSI300 (03188.HK) and MONTAGE TECH (06809.HK).
Shift in Investment Focus: Compared to 2025, South Korean investors are increasingly targeting China's emerging industries and tech companies, indicating a strategic shift in their investment approach.
Nomura Raises WUXI BIO (02269.HK) Price Target to $50.54 Following Strong Preliminary 2025 Results
WUXI BIO Profit Forecast: WUXI BIO projects a 16.7% YoY revenue growth for 2025, reaching RMB21.8 billion, surpassing market expectations of RMB21.5 billion.
Gross Margin and Net Profit Expectations: The company anticipates a gross margin increase to 46% and a net profit rise of 45.3% YoY to RMB5.7 billion, both exceeding market estimates.
Impact of WUXI XDC: Nomura highlights WUXI XDC as a key driver for revenue growth, with 2H25 revenue expected to grow by 12% YoY, up from 9% in 1H25.
Target Price Adjustment: Nomura raised WUXI BIO's target price from $37.36 to $50.54, maintaining a "Buy" rating based on the positive outlook.
Nomura Raises WUXI XDC (02268.HK) Price Target to $87.73, Anticipates 47% Profit Increase This Year
Nomura's Forecast Adjustment: Nomura has reduced its 2025 revenue and profit forecasts for WUXI XDC by 4.5% and 8.7%, respectively, based on recent company data.
Revenue Expectations: The broker projects revenue from commercial stage projects to reach RMB181 million and anticipates an additional RMB150 million from the acquisition of BIODLINK-B.
Profit Growth Projection: Nomura expects a 47% increase in profit for WUXI XDC in 2026, leading to an upward revision of the target price from $82.72 to $87.73.
Investment Rating: The rating for WUXI XDC has been maintained at "Buy" following the adjustments in forecasts and target price.
JPM Identifies Chinese Stocks Most Affected by RMB Appreciation's Negative Earnings Impact (Table)
Stock Performance Overview: Various stocks showed mixed performance with notable gains for SHENZHOU INTL (+2.953%) and SMIC (+2.061%), while others like UNIVERSAL SCIENTIFIC (-2.412%) and COWELL (-0.682%) experienced declines.
Short Selling Data: Significant short selling activity was observed, particularly in SMIC ($217.14M) and WUXI BIO ($160.63M), indicating market skepticism towards these stocks.
Estimated Impact of RMB Appreciation: The estimated impact of a 5% appreciation of the RMB against the USD on net profit varies, with some companies projected to face high single-digit impacts while others may see declines around 10-15%.
Market Outlook: UOB Kay Hian maintains a constructive medium-term view on markets, adding stocks like BABA and GANFENGLITHIUM to their buy list, while placing MEITUAN on the sell list.
G Sachs: This Year, China's Healthcare Sector Depends More on Data and Earnings Clarity; Favorable Outlook for CDMO Companies
Healthcare Sector Outlook: Goldman Sachs predicts that the strong trend in China's healthcare sector will continue, with stock trading increasingly focused on companies' execution capabilities and R&D pipelines rather than just licensing expectations.
CDMO Companies Favorable: The broker is optimistic about CDMO companies due to their growth potential and reasonable valuations, upgrading WUXI APPTEC and WUXI XDC to Buy.
Selective Biotech and Pharma Strategy: Goldman Sachs favors biotech and pharmaceutical companies with promising data releases and transaction expectations, highlighting SKB BIO-B, HENLIUS, and HANSOH PHARMA as favorable investments.
Cautious on Medical Services: The broker maintains a neutral stance on the medical devices sector and is cautious about medical services due to cost control measures and weak consumption, downgrading HYGEIA HEALTH and JXR to Neutral/Sell.
HSI Declines 11 Points at Midday; POP MART Soars Over 8%; Consumer Stocks Rise Against Market Trends
Market Performance: The HSI closed down 11 points at 26,552, with the HSCEI and HSTECH also experiencing slight declines. Total market turnover for the half-day was HKD129.845 billion.
Tech Stock Movements: Major tech stocks like TENCENT and BIDU-SW fell by approximately 1.5%, while JD-SW and BILIBILI-W saw gains of around 1.1% and 1.2%, respectively.
Sector Highlights: Consumer stocks performed well, with POP MART surging 8.5% after announcing a share buyback, while pharmaceutical stocks like HENGRUI PHARMA and WUXI APPTEC faced significant declines.
Economic Indicators: China's Fixed Asset Investment for December showed a year-on-year decrease of -3.8%, and the GDP growth rate for Q4 was reported at 4.5%, slightly below expectations.
